Compare ProShares UltraPro Short QQQ ETF (SQQQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro Short QQQ ETF vs Zimmer Biomet Holdings Inc — how do they compare? ProShares UltraPro Short QQQ ETF trades at $38.6, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while ProShares UltraPro Short QQQ ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| SQQQ | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $89.43 | $104.26 |
52-Week Low | $36.04 | $79.58 |
Market Cap | — | $17.97B |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are predominantly bearish, with moving averages signaling sell and oscillators neutral. The ETF is designed to gain when the Nasdaq-100 declines, but its structure leads to value erosion over time due to daily resets. Recent news highlights its use as a tactical hedge amid tech sector volatility but warns of long-term unsuitability.
The outlook for SQQQ is highly speculative and short-term oriented. It may offer tactical gains if tech stocks weaken, but structural decay and high volatility pose significant risks. Investors should view it as a hedging tool rather than a long-term holding, with success dependent on precise market timing and active management.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
